Nivolumab in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||27/04/2021|
|Rapid review completed||13/05/2021|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of nivolumab in combination with ipilimumab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.|
|Full pharmacoeconomic assessment commissioned by the HSE||31/05/2021|
|Pre-submission consultation with Applicant||20/07/2021|
|Full submission received from Applicant||21/01/2022|
|Preliminary review sent to Applicant||03/05/2022|
|NCPE assessment re-commenced||01/06/2022|
|Factual accuracy check sent to Applicant||29/07/2022|
|NCPE assessment re-commenced||10/08/2022|
|NCPE assessment completed||07/09/2022|
|NCPE assessment outcome||The NCPE recommends that nivolumab plus ipilimumab be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.